Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00387868 · ClinicalTrials.gov registry record · Phase 2
Preoperative Treatment of Patients With High Risk Thymoma
A Phase 2 study, sponsored by Valley Health System.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT00387868: Completed Phase 2 study, sponsored by Valley Health System.
NCT00387868 is a Phase 2 study that has completed, run by Valley Health System. The registered enrollment target is 21 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00387868, a Phase 2 study, has completed, sponsored by Valley Health System.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
This is a phase II study for patients with thymoma or thymic carcinoma thought to be at significant risk for recurrence following surgical removal. This study involves the use of combined chemotherapy and radiation therapy prior to surgery, in hopes of increasing the chances of complete resection. The chemoradiotherapy protocol is one which has been used extensively for other diseases, and the side effects are therefore well-documented. Patients with thymomas thought to be at significant risk for recurrence (by x-ray and pathology criteria) will be allowed to participate, and will undergo combined chemotherapy with radiation to the chest followed by surgical removal of the tumor and postoperative chemotherapy. The main outcome measured will be the rate of pathological complete response (e.g. no active tumor in the resected specimen) to the preoperative treatment. Patients will receive postoperative treatment based on surgical and pathologic criteria.
Interventions
- PROCEDURE Surgical Resection
- DRUG cisplatin and etoposide
- RADIATION Concurrent Radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2006-10 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
What the finished NCT00387868 record still lists
NCT00387868 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 3 interventions - of which Surgical Resection is the first listed.
NCT00387868 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00387868 about?
NCT00387868 is a clinical study titled "Preoperative Treatment of Patients With High Risk Thymoma". This is a phase II study for patients with thymoma or thymic carcinoma thought to be at significant risk for recurrence following surgical removal. This study involves the use of combined chemotherapy and radiation therapy prior to surgery, in hopes of increasing the chances of complete resection. T...
What is the current status of trial NCT00387868?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2006-10. Estimated completion is 2014-11.
What interventions are being tested in trial NCT00387868?
The interventions under investigation include: Surgical Resection (PROCEDURE), cisplatin and etoposide (DRUG), Concurrent Radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT00387868?
This trial is sponsored by Valley Health System, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00387868's enrollment target sits among peer trials
21 1794th of 2000 higher than 196 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia